Scancell Share Discussion Threads

[marcusl2] 14/4/2023 21:01

That abstract is not up to date. It says `A total of 21/138 patients have been treated to date.'


21 Feb
"To date, 23 patients have been vaccinated with Modi-1"



I am hoping for an update soon on Modi-1 data. Mon or Tue would be nice timing for Lindy explaining how the trial is going to the interested Big Pharma in Florida.

Further stable disease and additional partial responses would be welcome.

[inanaco] 14/4/2023 20:38

"""On reaching the tumor site the CD4 T cells release proinflammatory cytokines including, INFγ, which upregulates MHC class II and the same, but endogenous, modified peptides are presented on the tumor cell surface. This likely causes a positive feed-forward loop with killing of tumor cells."""

which is what we have always said ......... a feed back loop not dissimilar to nuclear fission

[ruckrover] 14/4/2023 19:03

"just remember Lindy is not a Oncologist but a ""BioChemist"""

LD Specialises in the treatment of cancer. Does that not make her an oncologist?

[inanaco] 14/4/2023 17:05

maybe you should watch ""Lorenzo's Oil""

[inanaco] 14/4/2023 17:03

just remember Lindy is not a Oncologist but a ""BioChemist""

[inanaco] 14/4/2023 16:59

Glycosylation
One of the most complex PTMs in the cell is glycosylation, which is a reversible enzyme-directed reaction (12). Glycosylation occurs in multiple subcellular locations, such as endoplasmic reticulum, the Golgi apparatus, cytosol and the sarcolemma membrane (80). Glycosylation occurs in eukaryotic and prokaryotic membranes and secreted proteins, also nearly 50% of the plasma proteins are glycosylated (14). In this modification, oligosaccharide chains are linked to specific residues by covalent bond (see Figures 3E and F). This enzymatic process, which is catalyzed by a glycosyltransferase enzyme, usually occurs in the side chain of residues such as Trp, Ala, Arg, Asn, Asp, Ile, Lys, Ser, Thr, Val, Glu, Pro, Tyr, Cys and Gly (6); however, it occurs more frequently on Ser, Thr, Asn and Trp residues in proteins and lipoproteins (13). According to the target residues, glycosylation can be classified into six groups: N-glycosylation, O-glycosylation, C-glycosylation, S-glycosylation, phosphoglycosylation and glypiation (GPI-anchored) (5, 12). N-glycosylation and O-glycosylation are two major types of glycosylation and have important roles in the maintenance of protein conformation and activity (81).

[inanaco] 14/4/2023 16:58

Scancell are experts at PTM .... moditope and Glymab novelties are related in that its a target caused by a reaction within the cell

""However, in many cancers, cell transformation accompanied by aberrant glycosylation results in the expression of abnormal glycans on tumour cells""

glycosylation

[inanaco] 14/4/2023 16:47

Overview
The DuoBody® platform is a versatile platform technology for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies (also known as dual-targeting molecules) bind to two different epitopes, either on the same or on different targets. This may improve the antibodies’ specificity and efficacy in inactivating the disease target cells. DuoBody®molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies, which allows DuoBody® molecules to be administered and dosed as other antibody therapeutics. Genmab’s DuoBody® platform generates bispecific antibodies via a fast and broadly applicable process that is easily performed at discovery scale as well as commercial manufacturing scale.

The DuoBody® platform serves as the basis of many bispecific antibodies in Genmab’s and our partners’ product pipeline. Two therapies have been approved created using DuoBody® technology platform, both developed and marketed by Janssen Biotech, Inc. The DuoBody® platform can be combined with Genmab’s HexaBody® platform (also known as Genmab’s technology platform DuoHexaBody®) as well as with other antibody engineering technologies.

[ruckrover] 14/4/2023 16:44

Small crow/Inan,Thanks for the responses.

[inanaco] 14/4/2023 16:40

ruckrover

Not Quite Genmab has acquired a MAB with a target ... its the target that is of interest, listen to the AGM speech .. by Lindy

peptide or glycan is a target and the peptides are also protected for use by an antibody by patent

scancell has retained the right to us gene therapy to generate chimeric t cells

so both Glycan and peptide can be both used for antibody and Car t / t cell

so the essence of the deal is a ""Target"" Genmab do not need antibodies they have there own DuoBody platform

[small crow] 14/4/2023 16:40

RR, An (natural) antibody is constructed from peptides and sugars but, in ordinary language I should imagine they use 'peptide' to mean a short protein molecule and not a much more complex antibody entity.

[octopus100] 14/4/2023 16:13

Well role on next week.
Lets just hope price has justification for staying at these levels and above.

[ruckrover] 14/4/2023 15:10

Inan,
My understanding from the RNS is that GenMab have licensed a mab not a peptide. They are different are they not?

[marcusl2] 14/4/2023 15:03

I wonder if SC88 will be the next deal. Only it and SC129 (Genmab) have the patents granted. The others are pending.

SC88 • Lewisacx
• Colorectal cancer

[inanaco] 14/4/2023 14:40

we have to now start considering each peptide as a vaccine ....

Like modi1 its 3 vaccines ........ not one vaccine

you could actually start tailoring the "mix" given .....

to the individual and to the target cancer

read the script

ATB

[inanaco] 14/4/2023 14:32

following on from scancells latest paper


In addition, we show that there is a CD4 T cell repertoire specific to three new citrullinated and three homocitrullinated epitopes present in healthy donors, namely Bip189-208cit, NPM266-285cit, Cyk8(101-120)cit, Aldo74-93hcit, Aldo140-157hcit and Vim116-135hcit. All T cell responses were predominantly Th1

I see 3 new peptides discovered

lets put that in to context

Genmab just paid $608m for one

back snoozing while the market catch's up that should increase trinity again ...

[chilltime] 14/4/2023 11:46

Thanks Bermuda

[bermudashorts] 13/4/2023 16:36

chilltime,

They are listed as co-authors because they're the clinical trial investigators for the modi-1 trial at their respective hospitals. As such they have responsibility for almost every aspect of the conduct of the trial, including ensuring that any scientific publications are accurate and reflect their contribution through the inclusion of their names. There will be a contract in place between Scancell and the investigators which will cover communication/publications and it's standard practice for both parties to be given an opportunity to approve/comment on official publications.

If you look back at all previous SCIB1 posters and publications relating to the clinical trial, you'll find that the study investigators are named as co-authors for the same reasons.

We only know for certain that Lindy Durrant is attending AACR - there is nothing to suggest that any of the other names will be attending in connection with Scancell.

[chilltime] 13/4/2023 15:47

5 of the presenters/authors are linked to 5 of the hospitals recruiting Moditope patients.

To list them means, the content will in some way cover patients recruited to those hospitals, no doubt to do with safety/efficacy.

[markingtime] 13/4/2023 14:43

I refer you to #57056 in which I suggested it would be "back at 21p or so" pre-conference..... .....so having ticked off that, I look forward to 40p or so by the end of the month. :-)

[888icb] 13/4/2023 14:16

Moving Up nicely againUp 6.4% at 20.75 on volume of 870000. 21p just paid for 30000. It looks likely that not only 20p has been taken out but 21p may soon follow.

[marcusl2] 13/4/2023 13:49

a reminder for any newbies...

These data drive increased confidence in the Moditope platform, leading to an uplift in our rNPV valuation to £300.1m, or 36.7p
probability on Moditope to 12.5% (from 10%)




(21st Feb 2023)
14 patients have reached the eight-week evaluation point, with no dose-limiting toxicities or safety concerns seen. Despite having failed at least one round of prior treatment and having progressive disease prior to study enrolment, one patient has a confirmed partial response and seven have stable disease.